Home Tags Regeneron Pharmaceuticals Inc.

Tag: Regeneron Pharmaceuticals Inc.

Regeneron named top biopharma employer by Science magazine

Regeneron is Science magazine's most highly ranked over the past decade, with first-place titles six of the past seven years and second-place ranking in 2015 and 2011.

FDA approves Regeneron, Sanofi skin cancer immuno-oncology drug

The drug is the first FDA-approved treatment for patients with advanced forms of a skin cancer known as cutaneous squamous cell carcinoma. 

BOMA to honor Hospital for Special Surgery, Regeneron at awards dinner

The event will be held on May 10 at Abigail Kirsch at Tappan Hill in Tarrytown

Regeneron partners with Alnylam to pursue liver disease treatment

The companies plan to research, co-develop and commercialize any therapeutics that emerge.

Regeneron names Marion McCourt senior VP and commercial head

Most recently, McCourt served as president and COO of Axovant, a clinical-stage biopharmaceutical company in Manhattan.

Ossining student among Regeneron science competition finalists

Skyler Jones, a senior at Ossining High School, is one of 40 finalists who were selected from a pool of 1,800 applicants.

Regeneron forms consortium to speed sequencing of UK Biobank data

The initiative that could support advances in the development of new medicines for a range of diseases.

Regeneron, Sanofi increase investment in drug developments

The companies will increase their investments in the development of cancer drug cemiplimab and food allergy drug dupilumab.

Greenburgh approves Regeneron’s planned 1 million-square-foot expansion

The Greenburgh town board approved the company’s site plan application earlier this month.

Regeneron expands operations in Ireland

The company will add 300 jobs to the bioprocessing campus and invest an additional $100 million.

Regeneron, Sanofi announce positive results for food allergy drug

Dupilumab showed positive results in adults with eosinophilic esophagitis, an allergic inflammatory disease that damages the esophagus.

Regeneron scraps development of drug for respiratory syncytial virus

Regeneron said a phase-3 study evaluating the antibody suptavumab did not meet its primary endpoint of preventing respiratory syncytial virus infections in infants.

Regeneron, Yonkers Partners in Education team up for STEM research institute

The Regeneron STEM Institute will offer designated Yonkers students the chance to choose a research topic and work with mentors from Regeneron's labs in Tarrytown and other parts of Westchester County.

Regeneron announces gene sequencing initiative with GSK, U.K. Biobank

The partnership initiative between the biobank, Regeneron Genetics Center, a subsidiary of Regeneron Pharmaceuticals, Inc., and GlaxoSmithKline will generate genetic sequence data from the volunteer participants of the U.K. Biobank.

A secret no more, BioInc@NYMC plots its future growth

For $100 per square foot, BioInc@NYMC can offer biotech startups access to expensive lab equipment, administrative space and professional services.